Longeveron Inc. 2023 Q3 Form 10-Q Summary
Business context and reporting period
Longeveron is a clinical-stage biotechnology company developing Lomecel-B™ cellular therapies for hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and aging-related frailty. The unaudited report covers the three and nine months ended September 30, 2023, compared with the corresponding 2022 periods.
Financial condition and key metrics
| Metric | Q3 2023 | Q3 2022 | 9M 2023 | 9M 2022 |
|---|---|---|---|---|
| Revenue | $0.15 million | $0.27 million | $0.65 million | $1.10 million |
| Gross profit | $0.05 million | $0.09 million | $0.22 million | $0.55 million |
| Gross margin | 36% | 35% | 35% | 50% |
| Operating loss | $5.16 million | $5.19 million | $15.59 million | $12.80 million |
| Net loss | $5.11 million | $5.24 million | $15.39 million | $14.38 million |
| Net loss attributable to common stockholders | $5.90 million | $5.24 million | $16.18 million | $14.38 million |
| Net loss per share | $0.28 | $0.25 | $0.77 | $0.69 |
| Net cash used in operating activities | Not separately provided | Not separately provided | $15.01 million | $11.66 million |
At September 30, 2023, cash and cash equivalents were $2.0 million, marketable securities were $2.0 million, working capital was approximately $1.7 million and total assets were $11.6 million. Total liabilities were $5.0 million, consisting primarily of lease liabilities and operating obligations; the filing reports no credit facility or other significant debt financing. Operating lease liabilities totaled approximately $2.2 million.
Accumulated deficit was $79.0 million. Management stated that existing cash and cash equivalents were expected to fund operating and capital requirements only into the first quarter of 2024 and that the company did not have sufficient cash to meet minimum expenditure commitments for one year from issuance of the financial statements. The filing therefore describes substantial doubt about the company’s ability to continue as a going concern.
Material changes versus the prior comparable period
- Revenue declined 43% in Q3 and 41% for the first nine months. The decrease reflected lower grant revenue and reduced participant demand in the Bahamas Registry Trial.
- Nine-month gross profit fell $0.3 million, and gross margin declined to 35% from 50%, primarily due to the revenue mix and lower grant-related activity.
- Quarterly operating expenses were broadly stable, but composition changed: general and administrative expense increased 49% to $3.1 million, while research and development expense decreased 38% to $1.8 million.
- For the first nine months, general and administrative expense increased 28% to $8.3 million and research and development expense increased 13% to $6.9 million, causing the operating loss to increase $2.8 million.
- Net cash used in operations increased to $15.0 million from $11.7 million. The company generated $6.6 million from investing activities, primarily by selling marketable securities, versus $0.1 million used in the prior-year period.
- The 2022 nine-month results included a $1.4 million securities lawsuit expense; the settlement was paid in May 2023. A former-employee dispute was also settled in September 2023, with $35,000 payable by Longeveron and remaining costs covered by insurance.
- A rights offering completed in September 2023 sold 108,497 Class A shares at $3.00 per share, but generated no net proceeds after approximately $0.3 million of expenses.
- A warrant down-round feature triggered by the rights offering reduced certain warrant exercise prices to $5.25 and resulted in a $0.8 million deemed dividend to common stockholders.
Guidance, outlook, risks and unusual items
- In October 2023, after quarter-end, Longeveron completed a registered direct offering and concurrent private placement that generated approximately $3.5 million of net proceeds. The financing included 2.365 million Class A shares, pre-funded warrants for 59,243 shares, and Series A and Series B warrants each covering up to 2.424 million shares. The warrants have a $1.65 exercise price and require stockholder approval to become exercisable.
- Management expects continued operating losses and plans to seek additional equity financing, grants, partnerships, licensing arrangements and other funding. Additional financing may substantially dilute existing stockholders.
- ELPIS II, the Phase 2 HLHS trial, was more than 50% enrolled, with enrollment planned for completion in 2024. Management reported that the completed ELPIS I study had 100% survival through age five in its 10 participants, compared with historical controls, but these results are preliminary and not a guarantee of future clinical success.
- The Phase 2a CLEAR MIND Alzheimer’s trial was completed in September 2023. Management reported positive safety and efficacy findings, including statistically significant improvements in certain secondary endpoints, while additional biomarker and other analyses remained pending.
- The Japan aging-related frailty trial is a 45-patient randomized, placebo-controlled Phase 2 study. The U.S. aging-related frailty program had five patients enrolled, with enrollment expected to be completed by the end of 2024.
- Key risks include clinical-trial failure, inability to obtain regulatory approval, competition, intellectual-property challenges, dependence on employees and collaborators, uncertain market acceptance, limited cash resources and the need for future capital.
- The company had approximately $1.9 million of expected master-services-agreement expenditures over the next two years, approximately $0.5 million of CRO payment obligations and $2.2 million of operating lease obligations at September 30, 2023.
- The company has no approved product and generates revenue primarily from grants, clinical trials and contract manufacturing. The filing does not provide a product-sales revenue forecast.
Important facts for investors to verify
- Confirm the post-quarter-end financing proceeds, share issuance, warrant terms and stockholder-approval conditions.
- Assess the company’s cash runway after the October financing against its $15.0 million nine-month operating cash burn and stated going-concern uncertainty.
- Track enrollment, trial milestones and regulatory interactions for ELPIS II, CLEAR MIND follow-up analyses and the aging-related frailty programs.
- Review potential dilution from the 2.424 million Series A warrants, 2.424 million Series B warrants, pre-funded warrants, existing warrants, options, RSUs and PSUs.
- Evaluate the sustainability of revenue from the Bahamas Registry Trial and the reduction in available unused grant funds, which declined to approximately $0.1 million from $0.8 million at December 31, 2022.
- Verify the company’s ability to secure additional financing or strategic partnerships before its projected cash runway expires.